SUMMIST: Surgery of Melanoma Metastases After Systemic Therapy
Study Details
Study Description
Brief Summary
To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
A Phase II Randomized Controlled Open-Label Parallel Group Interventional Multicenter Trial. Patients with metastatic melanoma, stratified for stage M1a or M1b/M1c, that have received first-line treatment with PD-1 inhibitors for a minimum of 9 months resulting in either partial response or stable disease according to RECIST 1.1 will be eligible. Patients will be screened for operability based on CT-scans examined by a multidisciplinary team, with the criteria that complete (R0) resection of all metastases should be possible. If the multidisciplinary team find that this would be possible, patients will be included and randomized 1:1 to either surgery with continued PD1-inhibition or current standard of care with continued PD1-inhibition only. At progression, treatment will be according to the treating medical oncologist. Active follow-up will be performed for 12 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: PD1-inhibitor + surgery Patients randomised to the interventional study arm, receiving both surgical metastasectomy and continued immunotherapy. Each patient case will be individually planned for surgery. Procedures will include, but will not be limited to, lung resections, liver resections, bowel resection, skin excisions and lymph node clearances. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist. |
Procedure: Surgical metastasectomy
Surgical removal of metastases aimed at R0 resection.
|
| Active Comparator: PD1-inhibitor Patients randomized to control study arm, receiving continued immunotherapy only. Patients in both study arms will continue with PD-1 inhibitor 12 months after randomization, and will then be treated according to their medical oncologist. |
Drug: Immunotherapy
Continued PD1-inhibitor treatment according to current treatment standards.
|
Outcome Measures
Primary Outcome Measures
- DFS 12 months [12 months]
Disease free survival
Secondary Outcome Measures
- SAE 12 months [12 months]
Serious adverse events
- Complications [3 months post operatively]
Surgical complications according to the Clavien-Dindo classification
- R0 resection [3 months post operatively]
Rate of R0 resections according to pathology report
- PFS 12 months [12 months]
Progression free survival
- MSS 12 months [12 months]
Melanoma specific survival
- OS 12 months [12 months]
Overall survival
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age above 18 years
-
Signed and dated written informed consent before the start of specific protocol procedures
-
Biopsy or cytology proven metastatic melanoma stage M1a, M1b or M1c
-
Have received a minimum of 9 months of immunotherapy (PD1-inhibitor alone or in combination) resulting in stable disease or partial response according to RECIST 1.1
-
Metastases judged to be radically resectable by surgery at a multidisciplinary conference
-
ECOG performance status 0-2
Exclusion Criteria:
-
Brain metastasis (M1d)
-
Previous treatment with BRAF/MEK inhibitors
-
Inability to understand given information or undergo study procedures according to protocol
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sahlgrenska University Hospital | Gothenburg | Sweden | 413 45 |
Sponsors and Collaborators
- Sahlgrenska University Hospital, Sweden
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SUMMIST